A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Who is this study for? Patients with locally advanced or metastatic non-small cell lung cancer refractory to 1st line immune checkpoint inhibitor-based therapy
What treatments are being studied? Atezolizumab+Tocilizumab
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
• Prior exposure to at least 1 line of therapy
• Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial
• ECOG PS 0-2
Locations
United States
Pennsylvania
Abramson Cancer Center of the University of Pennsylvania
RECRUITING
Philadelphia
Contact Information
Primary
Melissa Volpe, BA
melissa.volpe@pennmedicine.upenn.edu
215-220-9703
Backup
Melina Marmarelis, MD, MSCE
melina.marmarelis@pennmedicine.upenn.edu
215-615-5835
Time Frame
Start Date: 2023-07-25
Estimated Completion Date: 2027-09
Participants
Target number of participants: 28
Treatments
Experimental: Atezolizumab and Tocilizumab
Participants receive Atezolizumab 1200mg IV and Tocilizumab 6mg/kg IV (or Tocilizumab 4mg/kg IV) every 21 days
Related Therapeutic Areas
Sponsors
Collaborators: Genentech, Inc.
Leads: Abramson Cancer Center at Penn Medicine